A biotech company reports that an experimental treatment elongated its CEO’s telomeres.
July 27, 1987|
LONDON—Genentech's British patent on the blood clot-dissolving tissue plasminogen activator (TPA) has been revoked after a three-week trial that featured some of the world's leading biotechnologists. But High Court Justice John Whitford was not persuaded by the assertion of Nobel laureate Paul Berg of Stanford that Genentech had a monopoly on the skills needed to make TPA by recombinant DNA techniques when it filed its patent application in May 1983. Biochemist WJ. Brammar of the Universit